DELTAREX-G TUMOR AGNOSTIC THERAPY SHOWS CLINICAL BENEFIT IN CHEMORESISTANT STAGE 4 SARCOMA, PANCREATIC AND BREAST CANCER

April 15, 2024 11:00 PM AEST | By EIN Presswire

Google News:

DELTAREX-G TUMOR AGNOSTIC THERAPY SHOWS CLINICAL BENEFIT IN CHEMORESISTANT STAGE 4 SARCOMA, PANCREATIC AND BREAST CANCER — Image source: EIN Presswire

Recent News

Global energy stocks dip as US Senate moves to end wind, solar tax cre...

ASX 200: Real Estate and Tech Lift Sentiment Amid Market Caution

Woodside Energy (ASX:WDS) Faces Setback on ASX 200 Amid Oil Retreat

ASX 200: BHP, Rio Tinto, Pilbara Minerals & More in Focus as Aussie Sh...

LOS ANGELES, CALIFORNIA, USA, April 15, 2024 /EINPresswire.com/ -- The Aveni Foundation and the Sarcoma Oncology Research Center, Santa Monica CA, are proud to announce that AI analysis of tumors from patients with pancreatic cancer, sarcoma, breast cancer, Sertoli cell tumor, adenocarcinoma of appendix and urothelial cell carcinoma showed enhanced CCNG1 expression
(Cancer Res (2024) 84 (6_Supplement): 5183. https://doi.org/10.1158/1538-7445.AM2024-5183). CCNG1, a non-canonical cyclin, is a novel biomarker in development for partnering with DRG-101 (DeltaRex-G), a tumor-targeted retrovector encoding a CCNG1 inhibitor gene. Expanded access for DeltaRex-G as monotherapy or with FDA approved drugs (DeltaRex-G+) is currently open for an intermediate-size population of advanced pancreatic cancer, sarcoma, and carcinoma of breast (NCT04091295). Therefore, it is important to identify patients who might respond favorably to DeltaRex-G gene therapy. Previously, we reported that CCNG1 expression is enhanced in sarcoma tumors (Chawla et al., Ann Oncol 34, 1980P, 2023). In this report, we have expanded the analysis to 137 patients with all cancer types and report clinical benefit in patients with enhanced CCNG1 expression levels who have been treated with DeltaRex-G.
Historically, one patient with metastatic pancreatic cancer, one with early-stage HR+ HER2+ invasive breast cancer, and one with early-stage triple-negative breast cancer are alive 15, 3, and 2.5 years in sustained remission, respectively, with DeltaRex-G therapy (Chawla et al., Anticancer Res 43: 2383-2391 (2023). doi:10.21873/anticanres.16406). These three patients had 24%, 23%, and 74% CCNG1 tumor expression levels, respectively. Five patients with sarcoma, pancreatic and breast cancer who are currently receiving DeltaREx-G in combination with FDA approved drugs had partial responses and stable disease with no treatment-related side effects. The authors conclude that DeltaRex-G+ is a uniquely safe and effective regimen for heavily treated patients with Stage 4 pancreatic cancer, sarcoma and breast cancer. According to Dr. Vaishali Kumar, "DeltaRex-G, a CCNG1 inhibitor, is a tumor agnostic gene therapy with numerous clinical applications since CCNG1 is enhanced in all cancerous tumors that have been tested so far".

For further information, please go to the following websites: www.avenifoundation.org, www.sarcomaoncology.com or contact Dr. Gordon at [email protected] or [email protected]. To make a donation, please visit our website at www.avenifoundation.org and click on the “donate” button for credit card donations.

Erlinda M Gordon
Aveni Foundation
+1 818-726-3278
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.